Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment
From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology.
At this year's EHA Congress, a study from Italy (abstract S231) explored the differences in the efficacy and survival outcomes of CAR-T cell therapy for different subtypes of B-cell lymphoma patients, drawing significant attention. To gain a deeper understanding of this study, Oncology Frontier conducted an exclusive interview with Professor Wang Huaqing from Tianjin People's Hospital of Nankai University, who provided detailed insights into the research.
